Vectura signs global development agreement with Dynavax
Wiltshire-based pharmaceuticals business Vectura Group announced it had signed an exclusive agreement with NASDAQ listed company Dynavax Technologies.
FTSE 250
19,601.98
17:09 25/04/24
FTSE 350
4,434.34
17:09 25/04/24
FTSE All-Share
4,387.94
16:49 25/04/24
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
Vectura Group
164.80p
16:53 18/10/21
The agreement with Dynavax, a clinical-stage immunotherapy company, is for the clinical application of Vectura's proprietary smart nebuliser technology AKITA, to deliver its investigational immunotherapeutic agent DV281 to lung cancer patients.
The agreement covers the Phase I and II development programmes, with Vectura providing devices and support to Dynavax, which will be running the programme itself.
James Ward-Lilley, Chief Executive Officer, said, "The collaboration with Dynavax is an exciting innovative programme combining the development of a new treatment option for patients with lung cancer along with targeted inhaled delivery. This agreement underlines the increasing recognition of the utility of Vectura's unique smart nebuliser technology and devices by existing and potential development partners."
As of 0930 BST, Vectura shares had nudged ahead 1.24% to 113.90p.